glp-1 with cv benefit Could receptor agonists improve long-term outcomes for patients peripheral artery disease? New research found that patients with #PAD and type 2 diabetes treated with GLP-1 therapy had lower rates of GLP-1 receptor agonist therapy for

NMN NMN (Nicotinamide Mononucleotide) is recognized for its ability to enhance NAD (Nicotinamide Adenine Dinucleotide) levels, a critical molecule for energy production in cells

It seems to last a reasonable amount of time , depending on how frequently its used

Moroo I, Yamada T, Makino H, Tooyama I, McGeer PL, McGeer EG, et al

While they may not always occur, they are more likely to do so when first restarting a GLP-1 or when increasing the dose

Dual incretin (GIP/GLP-1) injection approved for diabetes, with strong weight-loss outcomes

Deep Vein Thrombosis (DVT) vs Pulmonary Embolism (PE) DVT and PE are not the same condition, though they are related